A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Study Summary

This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).

Conditions

Polycythemia Vera (PV)

Interventions / Drugs

DISC-3405

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment60 participants

Primary Completion—

Lead SponsorDisc Medicine, Inc

Data Retrieved2026-04-11 04:18:08.225399+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.